Evotec SE has joined the NURTuRE-AKI consortium, a pivotal initiative to create the world's most comprehensive patient cohort for Acute Kidney Injury (AKI). This partnership will significantly advance Evotec's molecular understanding of AKI, aiming to discover innovative treatments for this critical condition.

AKI, a sudden decline in kidney function, carries high mortality and often leads to chronic kidney disease (CKD). With no current treatments, there's a significant unmet medical need. Common causes include blood pressure changes and contrast agents used in cardiac surgeries.

The NURTuRE-AKI study is a three-year longitudinal effort, collecting biological samples and clinical data from adult and pediatric cardiac surgery patients at high risk for AKI, and those progressing to CKD. These samples, from 13 UK NHS Trusts, will undergo advanced omics analyses, creating an unparalleled global resource. Sub-cohorts include 400 adult cardiac surgery patients, 150 pediatric cardiac surgery patients, and 400 adults with persistent renal failure. Crucially, the study will integrate linked clinical data from the UK Renal Registry.

Integrating NURTuRE-AKI data into Evotec's proprietary Molecular Patient Database (E.MPD), which houses multi-omics data (PanOmics) and clinical records, will dramatically enhance Evotec's understanding of human diseases and boost its precision medicine, drug discovery, and development programs.

The NURTuRE-AKI consortium is a collaborative effort funded by Evotec, AstraZeneca, Nephrolyx, and Kidney Research UK, with academic oversight from Leeds Teaching Hospital NHS Trust, University of Bristol, and University Hospital Birmingham. Evotec, a leader in AI-driven drug discovery across various modalities and therapeutic areas, sees this venture as a significant expansion of its leadership in kidney disease research, aiming to transform global treatment for AKI.